iCAD INC.

iCAD Inc. is a global leader in AI-powered breast health diagnostic solutions. The company develops and markets the ProFound Breast Health Suite, a clinically proven platform designed to improve breast cancer detection, density assessment, and risk evaluation. ProFound offers three core components: Detection (for 2D and 3D digital mammography and tomosynthesis), Density Assessment (for objective breast density scoring), and Risk Evaluation (an image-based risk model reported to be 2.4x more accurate than traditional models). The company serves radiology practices, imaging centers, and hospitals globally, with operations in over 50 countries. iCAD has processed more than 40 million mammograms worldwide in the past five years, with approximately 30% being tomosynthesis cases. The platform integrates seamlessly with major PACS and mammography workstations from vendors including Hologic, GE Healthcare, Siemens Healthineers, Canon, Fujifilm, Konica Minolta, Philips, and others. ProFound Detection and Density Assessment products are FDA-cleared and CE-marked. ProFound AI Risk is CE-marked and Health Canada-licensed but not FDA-cleared in the US (investigational use only). The company emphasizes rapid implementation, flexible deployment options (on-premises and cloud), and workflow integration. As of July 2025, iCAD was acquired by RadNet, Inc. (through its subsidiary DeepHealth). Founded with deep clinical research backing, iCAD collaborates with leading research institutions and maintains extensive partnerships with healthcare IT platforms and imaging manufacturers.